NewAmsterdam Pharma lands $196m Series A
NewAmsterdam Pharma, a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has raised $196 million in Series A funding.
NewAmsterdam Pharma, a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has raised $196 million in Series A funding.
Copyright PEI Media
Not for publication, email or dissemination
